[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"medium-vessel-occlusion-stroke-mevo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:medium-vessel-occlusion-stroke-mevo":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":4},"100657888","sail-mevo-endovascular-treatment-versus-best-medical-therapy-for-distal-vessel-occlusions-100657888",false,"NCT07843797","SAIL-MEVO: Endovascular Treatment Versus Best Medical Therapy for Distal Vessel Occlusions","SAIL-MEVO: Endovascular Treatment Versus Best Medical Therapy for Distal Vessel Occlusions - Randomized Controlled Trial","SAIL MEVO","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Pre-stroke modified Rankin Scale (mRS) score of 0-1.\n* Baseline NIH Stroke Scale (NIHSS) score between 9 and 17.\n* Symptom onset to randomization less than 12 hours.\n* Acute ischemic stroke due to an isolated medium\u002Fdistal vessel occlusion involving a non-dominant M2-M3 middle cerebral artery, A2-A3 anterior cerebral artery, or P2-P3 posterior cerebral artery confirmed by CTA or MRA.\n* Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on non-contrast CT AND AI-predicted infarct core volume \\\u003C10 mL on non-contrast CT (when available) AND AI-defined Tmax \\>6s volumen \\>30cc on CTP (when available).\n* Written informed consent obtained from the participant or a legally authorized representative in accordance with local regulations.\n\nExclusion Criteria:\n\n* Proximal large vessel occlusion (internal carotid artery or M1 segment) or tandem cervical internal carotid artery stenosis \\>70%.\n* Intracranial hemorrhage at baseline imaging.\n* Pregnancy.\n* Life expectancy less than 3 months.\n* Severe allergy to iodinated contrast media.","ALL","18 Years","80 Years",{"count":21,"type":22},420,"ESTIMATED","INTERVENTIONAL",[25],"NA","Patients with acute ischemic stroke caused by distal or medium vessel occlusions (MeVOs) may experience significant disability despite receiving the current standard medical treatment. Although endovascular treatment (EVT) is an established therapy for large vessel occlusions, its benefit in MeVO stroke remains uncertain.\n\nThe SAIL-MEVO trial is a prospective, multicenter, randomized controlled trial designed to evaluate whether EVT combined with best medical therapy improves functional outcomes compared with best medical therapy alone in selected patients with acute ischemic stroke due to MeVO. Eligible participants will be randomized in a 1:1 ratio to receive either best medical therapy alone or best medical therapy plus EVT using a standardized stepwise approach consisting of aspiration thrombectomy (ADAPT) followed, when necessary, by the SAIL technique (stent retriever-assisted intra-arterial lysis).\n\nThe primary objective is to determine whether EVT increases the proportion of patients achieving functional independence (modified Rankin Scale score 0-2) at 90 days after stroke. Secondary objectives include assessment of neurological recovery, infarct volume, quality of life, patient-reported outcomes, safety, and procedural outcomes.",[28,29,30,31],"Medium Vessel Occlusion Stroke (MeVO)","Stroke Acute","Acute Ischemic Stroke","Cerebral Artery Occlusion",[33,34,35,36,37,38,39,40,41,42,30,43,44,45,46,47,48,49],"Distal Vessel Occlusion","Medium Vessel Occlusion","MeVO","Endovascular Treatment","Mechanical Thrombectomy","Aspiration Thrombectomy","ADAPT","SAIL","Intra-Arterial Thrombolysis","Randomized Controlled Trial","Modified Rankin Scale","NIHSS","AI Imaging","Infarct Core","Neurointervention","Stroke","PROBE Trial","NOT_YET_RECRUITING","2026-09-23",{"date":53,"type":54},"2026-09-28","ACTUAL",{"date":56,"type":22},"2026-10",{"date":58,"type":22},"2029-07",{"name":60,"class":61},"Hospital Universitari Vall d'Hebron Research Institute","OTHER"]